[1]
Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present--a pharmacological and clinical perspective. Journal of psychopharmacology (Oxford, England). 2013 Jun:27(6):479-96. doi: 10.1177/0269881113482532. Epub 2013 Mar 28
[PubMed PMID: 23539642]
Level 3 (low-level) evidence
[2]
Ermer JC, Pennick M, Frick G. Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy. Clinical drug investigation. 2016 May:36(5):341-56. doi: 10.1007/s40261-015-0354-y. Epub
[PubMed PMID: 27021968]
[3]
Nickell JR, Siripurapu KB, Vartak A, Crooks PA, Dwoskin LP. The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse. Advances in pharmacology (San Diego, Calif.). 2014:69():71-106. doi: 10.1016/B978-0-12-420118-7.00002-0. Epub
[PubMed PMID: 24484975]
Level 3 (low-level) evidence
[4]
Miller GM. The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. Journal of neurochemistry. 2011 Jan:116(2):164-76. doi: 10.1111/j.1471-4159.2010.07109.x. Epub
[PubMed PMID: 21073468]
[5]
Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management, Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, Feldman HM, Ganiats TG, Kaplanek B, Meyer B, Perrin J, Pierce K, Reiff M, Stein MT, Visser S. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011 Nov:128(5):1007-22. doi: 10.1542/peds.2011-2654. Epub 2011 Oct 16
[PubMed PMID: 22003063]
Level 1 (high-level) evidence
[6]
Daughton JM, Kratochvil CJ. Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls. Journal of the American Academy of Child and Adolescent Psychiatry. 2009 Mar:48(3):240-248. doi: 10.1097/CHI.0b013e318197748f. Epub
[PubMed PMID: 19242289]
[7]
Gautam M, Prabhakar D. Stimulant Formulations for the Treatment of Attention-Deficit/Hyperactivity Disorder. The primary care companion for CNS disorders. 2018 Dec 27:20(6):. pii: 18r02345. doi: 10.4088/PCC.18r02345. Epub 2018 Dec 27
[PubMed PMID: 30605269]
[8]
Richardson E, Seibert T, Uli NK. Growth perturbations from stimulant medications and inhaled corticosteroids. Translational pediatrics. 2017 Oct:6(4):237-247. doi: 10.21037/tp.2017.09.14. Epub
[PubMed PMID: 29184805]
[9]
Berman SM, Kuczenski R, McCracken JT, London ED. Potential adverse effects of amphetamine treatment on brain and behavior: a review. Molecular psychiatry. 2009 Feb:14(2):123-42. doi: 10.1038/mp.2008.90. Epub 2008 Aug 12
[PubMed PMID: 18698321]
[10]
Sichilima T, Rieder MJ. Adderall and cardiovascular risk: A therapeutic dilemma. Paediatrics & child health. 2009 Mar:14(3):193-5
[PubMed PMID: 20190905]
[11]
Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O'Duffy A, Connell FA, Ray WA. ADHD drugs and serious cardiovascular events in children and young adults. The New England journal of medicine. 2011 Nov 17:365(20):1896-904. doi: 10.1056/NEJMoa1110212. Epub 2011 Nov 1
[PubMed PMID: 22043968]
[12]
Schelleman H, Bilker WB, Strom BL, Kimmel SE, Newcomb C, Guevara JP, Daniel GW, Cziraky MJ, Hennessy S. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics. 2011 Jun:127(6):1102-10. doi: 10.1542/peds.2010-3371. Epub 2011 May 16
[PubMed PMID: 21576311]
[13]
Feinberg SS. Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. The Journal of clinical psychiatry. 2004 Nov:65(11):1520-4
[PubMed PMID: 15554766]
[14]
Leonard JB, Howard AK, Hines EQ. Toxicity of acute exploratory amphetamine-salt medication in amphetamine-naïve pediatrics: a retrospective cohort study. Clinical toxicology (Philadelphia, Pa.). 2020 Sep:58(9):907-912. doi: 10.1080/15563650.2019.1703997. Epub 2020 Jan 8
[PubMed PMID: 31913713]
Level 2 (mid-level) evidence
[15]
Steinkellner T, Freissmuth M, Sitte HH, Montgomery T. The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine. Biological chemistry. 2011 Jan:392(1-2):103-15. doi: 10.1515/BC.2011.016. Epub
[PubMed PMID: 21194370]
[16]
Yamamoto BK, Moszczynska A, Gudelsky GA. Amphetamine toxicities: classical and emerging mechanisms. Annals of the New York Academy of Sciences. 2010 Feb:1187():101-21. doi: 10.1111/j.1749-6632.2009.05141.x. Epub
[PubMed PMID: 20201848]
[17]
Docherty JR, Green AR. The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives. British journal of pharmacology. 2010 Jul:160(5):1029-44. doi: 10.1111/j.1476-5381.2010.00722.x. Epub
[PubMed PMID: 20590597]
[18]
Richards JR, Albertson TE, Derlet RW, Lange RA, Olson KR, Horowitz BZ. Treatment of toxicity from amphetamines, related derivatives, and analogues: a systematic clinical review. Drug and alcohol dependence. 2015 May 1:150():1-13. doi: 10.1016/j.drugalcdep.2015.01.040. Epub 2015 Feb 18
[PubMed PMID: 25724076]
Level 1 (high-level) evidence